AbbVie and Simcere Zaiming announced a licensing option agreement to develop SIM0500, a trispecific antibody targeting multiple myeloma. Currently in Phase I trials, SIM0500 induces strong...
BaseLaunch, a Basel biotech incubator, gains support from AbbVie, joining Roche, Novo Nordisk, Johnson & Johnson, and CSL Behring. Operated by Basel Area Business & Innovation,...